7月，最新一期Cell Stem Cell雜志發(fā)表了3個研究團(tuán)隊的最新研究成果,，研究者成功的將人體血細(xì)胞轉(zhuǎn)化為iPS細(xì)胞,。專家稱這些研究加快了干細(xì)胞技術(shù)應(yīng)用。日本京都大學(xué)科學(xué)家山中伸彌（Shinya Yamanaka）特別為本期Cell Stem Cell發(fā)表評論文章稱這三項研究是干細(xì)胞領(lǐng)域發(fā)展的巨大進(jìn)步,。
2010年度日本京都獎揭曉山中伸彌因干細(xì)胞研究獲先進(jìn)技術(shù)獎
全球干細(xì)胞研究領(lǐng)域20位頂尖科學(xué)家——第一位Shinya Yamanaka
干細(xì)胞之春——生物谷盤點2009
干細(xì)胞發(fā)展編年史
2010十大新興技術(shù)（TR10）,，醫(yī)學(xué)生物技術(shù)占三席
三年前，來自日本和美國的研究人員稱他們已經(jīng)將人的表皮細(xì)胞轉(zhuǎn)化為iPS細(xì)胞,。這周,，3個研究小組稱從血液中獲得了iPS細(xì)胞。此前人們通常采集皮膚細(xì)胞來制作iPS細(xì)胞,，耗時長達(dá)六七十天,。新技術(shù)極大地縮短了時間，從血液采集算起只需要25天,。新方法可以使用驗血時采集的血液,。研究者將目光瞄準(zhǔn)了血液中富含的一種淋巴細(xì)胞“T細(xì)胞”，從0.1毫升的血液中提取T細(xì)胞,，再通過“仙臺病毒”將制作iPS細(xì)胞所需的4種特定基因?qū)隩細(xì)胞中,。該病毒即使感染了細(xì)胞，也只會停留在細(xì)胞質(zhì)中,，不會侵入細(xì)胞核,，因此不會損傷細(xì)胞DNA,，具有細(xì)胞癌變風(fēng)險低的優(yōu)點。研究人員已確認(rèn),，制成的iPS細(xì)胞中不含仙臺病毒,，可以分化成各種體細(xì)胞。
美國賓尼法尼亞州大學(xué)再生醫(yī)學(xué)研究所John Gearhart博士稱,，這三篇文章對于iPS領(lǐng)域來說非常重要,，血液細(xì)胞轉(zhuǎn)化獲得iPS細(xì)胞，這為研究者和患者提供了便利,。(生物谷Bioon.net)
山中伸彌發(fā)表的評論文章：
Cell Stem Cell doi:10.1016/j.stem.2010.06.009
Patient-Specific Pluripotent Stem Cells Become Even More Accessible
Shinya Yamanaka
1 Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 606-8507, Japan
2 Gladstone Institute of Cardiovascular Disease, San Francisco, CA 94158, USA
In this issue of Cell Stem Cell, Staerk et al. (2010), Seki et al. (2010),Staerk et al. (2010), Seki et al. (2010), and Loh et al. (2010) each describe the derivation of human iPSCs from peripheral blood. Although seemingly incremental, this advance brings the stem cell field an important step closer to eventual clinical use.
生物谷推薦Tomohisa Seki等發(fā)表文章的索引
Cell Stem Cell doi:10.1016/j.stem.2010.06.003
Generation of Induced Pluripotent Stem Cells from Human Terminally Differentiated Circulating T Cells
Tomohisa Seki1, 7, Shinsuke Yuasa1, 2, 7, Mayumi Oda2, Toru Egashira1, Kojiro Yae1, Dai Kusumoto1, Hikari Nakata1, Shugo Tohyama1, Hisayuki Hashimoto1, Masaki Kodaira1, Yohei Okada2, 3, Hiroyuki Seimiya4, Noemi Fusaki5, 6, Mamoru Hasegawa5 and Keiichi Fukuda1
1 Department of Cardiology, Keio University School of Medicine, Tokyo 160-8582, Japan
2 Center for Integrated Medical Research, Keio University School of Medicine, Tokyo 160-8582, Japan
3 Department of Physiology, Keio University School of Medicine, Tokyo 160-8582, Japan
4 Division of Molecular Biotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan
5 DNAVEC Corporation, Ibaraki 1-25-11, Japan
6 PRESTO, JST, Saitama 332-0012, Japan
